Avalo Therapeutics, Inc. (AVTX), the clinical-stage biotechnology company announced the appointment of Jennifer Riley as chief strategy officer with effect from January 1. Shares are down 1.75 percent in the pre-market.
Riley will be responsible for managing corporate strategy and planning the commercial and product pipeline, aiming to boost growth and innovation in the company. She has over 20 years of experience in the biotechnology and pharmaceutical industries.
Thursday, AVTX had closed 4.74% less at $7.43 on the Nasdaq. In the pre-market trading, AVTX is 1.75% high at $7.30.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.